Try our beta test site

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

This study has been completed.
Sponsor:
Collaborators:
AstraZeneca
University of Iowa
Mclean Hospital
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00880919
First received: April 10, 2009
Last updated: January 26, 2017
Last verified: January 2017
  Purpose

The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to assess effectiveness and safety while maximizing retention. The specific aim is to determine if Seroquel XR is superior to placebo. The primary outcome measure will be a statistically significant difference between Seroquel XR compared to placebo on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), an objective rating scale that addresses the severity of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of the illness. As there is the recent development of an extended release form of Seroquel (Seroquel XR) (Schulz et al. 2007), the new compound may offer several advantages in this study. Therefore, the hypothesis of this study is that both doses of Seroquel XR (see below) will be superior to placebo in an 8-week randomized trial as assessed by the ZAN-BPD.

To achieve the Primary Objective of this study, two doses of Seroquel XR will be tested - 150 mg/d and 300 mg/d. Thus, the study will be able to assess the effect of Seroquel XR compared to placebo and to explore a dose effect.


Condition Intervention Phase
Borderline Personality Disorder
Drug: quetiapine extended-release
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Resource links provided by NLM:


Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) [ Time Frame: baseline, weekly until week 8 ]
    This is an assessment of change in DSM-IV borderline psychopathology. Consisting of nine criteria rated on a five-point anchored rating scale of 0 to 4, yielding a total score of 0 to 36. 0 being the best and 4 meaning the worse.

  • Montgomery-Åsberg Depression Rating Scale (MADRS) [ Time Frame: baseline to 8 weeks ]

    Nine criteria rated on a six-point anchored rating scale of 0 to 6, yielding a total score of 0 to 60. O is the least and 6 is the highest

    0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression.


  • Borderline Evaluation of Severity Over Time (BEST) [ Time Frame: Baseline to 8 weeks ]
    Scale including 15 items and three subscales. All items are rated on a Likert-like scale. A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).

  • Overt Aggression Scale - Modified (OAS-M) [ Time Frame: Change from Baseline Overt Aggression Scale - Modified to 8 weeks ]
    Four part behavior rating scale designed to measure four types of aggressive behavior as witnessed in the past week. Each section consists of five questions. Total scores on the MOAS range from 0-40. 0 is the best and 40 is the worst of symptoms Reduction in scores shows a change of symptoms.

  • Global Assessment of Functioning Scale (GAF) [ Time Frame: Change in Global Assessment of Functioning from Baseline to 8 weeks ]
    Numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults. 100 is the highest level of functioning. O is the least functional

  • Barratt Impulsiveness Scale (BIS) [ Time Frame: Change in Impulsiveness from Baseline to 8 weeks ]
    30-item self-report questionnaire, that is scored to yield a total score, three second-order factors, and six first-order factors. patients rate the questions 1-4 1 being the least and 4 being the most.

  • Symptom Checklist -90-Revised (SCL-90-R) [ Time Frame: Change in psychological problems and symptoms from Baseline to 8 weeks ]
    90 items measured on a Likert scale via self-report. Scale is 0-5 stating 0= strongly disagree and 5 is Strongly agree Measures psychological problems and symptoms

  • Young Mania Rating Scale (YMS) [ Time Frame: Change in manic symptoms from Baseline to 8 weeks ]
    Eleven-item multiple choice diagnostic questionnaire, yielding total scores of 0-60. 0-4 rating 0-being least likely and 4 being most likely This scale assess manic symptoms

  • Sheehan Disability Scale (SDS) [ Time Frame: Change in functional impairment from Baseline to 8 weeks ]
    Three self-rated items, on a scale of 0-10. 0 is unimpaired 10 is highly impaired This measures functional impairment


Enrollment: 95
Study Start Date: June 2008
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Seroquel XR 150mg oral tablets taken daily for 8 weeks.
Drug: quetiapine extended-release
Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Other Name: Seroquel XR
Active Comparator: 2
Seroquel XR 300mg oral tablets taken daily for 8 weeks.
Drug: quetiapine extended-release
Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Other Name: Seroquel XR
Placebo Comparator: 3
Equivalent number of placebo oral tablets taken daily for 8 weeks.
Drug: Placebo
Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Other Name: quetiapine extended-release

Detailed Description:

The secondary objectives in this study are aimed at answering further questions regarding symptom assessments, dosing strategies, and safety. The specific secondary objectives are listed below:

  1. Response rate: In previous studies using the ZAN-BPD, response was defined as a 50% reduction of ZAN-BPD scores. Response rates will be compared between Seroquel XR and placebo.
  2. Other Symptom Measures: Over the last twenty years, other rating scales of a general nature have been used to assess BPD patients in clinical trials. To fully assess the patients as they progress through the study, the following scales will be administered: Symptom Checklist 90 - Revised (SCL-90 R), Montgomery Asberg Depression Rating Scale (MADRS), Barratt Impulsivity Scale (BIS), Schedule for Interviewing Borderlines (SIB), Overt Aggression Scale - Modified (OAS-M), Young Mania Rating Scale (YMRS), the Borderline Evaluation of Severity over Time (BEST), and the Global Assessment of Function (GAF).
  3. Side-Effects: To be able to report the safety of Seroquel XR for BPD, a combination of objective and subjective measures will be employed. Objectively, weight, height (and Body Mass Index (BMI)), prolactin, glucose, cholesterol and triglycerides will be assessed at baseline and endpoint. Objective ratings of movement side effects will be performed using Simpson Angus Scale (SAS) (Simpson and Angus 1970), Barnes Akathisia Scale (BAS) (Barnes 1989), and Abnormal Involuntary Movement Scale (AIMS) (Guy 1976), and at baseline and endpoint. Regarding possible side effects reported by patients, their reports of headache, somnolence, and other experiences will be tabulated.

Secondary objective data will be analyzed as continuous variable data over the time of the study or, when appropriate, comparisons of baseline to endpoint will be made.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consent
  • A diagnosis of borderline personality disorder (301.83)
  • All subjects will have a ZAN-BPD greater or equal to 9 at randomization.
  • Males and females aged 18-45 years
  • Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrollment
  • Able to understand and comply with the requirements of the study

Exclusion Criteria:

  • Pregnancy or lactation
  • Any DSM-IV Axis I disorder not defined in the inclusion criteria. The patients with BPD may not have bipolar I disorder, schizophrenia, schizoaffective disorder, delirium, or dementia. Neither may they have current DSM-IV substance dependence.
  • Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
  • Known intolerance or lack of response to quetiapine fumarate, as judged by the investigator
  • Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrollment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir
  • Use of any of the following cytochrome P450 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids
  • Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomization
  • Substance or alcohol dependence at enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria
  • Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV criteria within 4 weeks prior to enrollment
  • Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
  • Unstable or inadequately treated medical illness (e.g. diabetes, angina pectoris, hypertension, congestive heart failure) as judged by the investigator
  • Involvement in the planning and conduct of the study
  • Previous enrollment or randomization of treatment in the present study.
  • Participation in another drug trial within 4 weeks prior enrollment into this study or longer in accordance with local requirements
  • Unstable Diabetes Mellitus
  • An absolute neutrophil count (ANC) of 1.5 x 109 per liter
  • Past history of lack of response to an atypical antipsychotic medication or substantial previous side effects will be cause for exclusion.
  • Any medical illness that would interfere with conduct of the study will be cause for exclusion.
  • Pregnant or lactating women and women of childbearing potential not using medically accepted means of contraception.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00880919

Locations
United States, Iowa
University of Iowa, Department of Psychiatry
Iowa City, Iowa, United States, 52242
United States, Massachusetts
McLean Hospital, Harvard Medical School, Department of Psychiatry
Belmont, Massachusetts, United States, 02478
United States, Minnesota
University of Minnesota Medical Center, Fairview Riverside
Minneapolis, Minnesota, United States, 55454
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
AstraZeneca
University of Iowa
Mclean Hospital
Investigators
Principal Investigator: S. Charles Schulz, MD University of Minnesota - Clinical and Translational Science Institute
  More Information

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT00880919     History of Changes
Other Study ID Numbers: 0709M16844
IRUSQUET0454 ( Other Grant/Funding Number: AstraZeneca )
Study First Received: April 10, 2009
Results First Received: April 16, 2014
Last Updated: January 26, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Borderline Personality Disorder
BPD
Seroquel
Seroquel XR
quetiapine
quetiapine extended-release

Additional relevant MeSH terms:
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs

ClinicalTrials.gov processed this record on March 24, 2017